miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

BACKGROUND: While the treatment of HER2 over-expressing breast cancer with recent HER-targeted drugs has been highly effective for some patients, primary (also known as innate) or acquired resistance limits the success of these drugs. microRNAs have potential as diagnostic, prognostic and predictive...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer
Main Authors: Corcoran, Claire, Rani, Sweta, Breslin, Susan, Gogarty, Martina, Ghobrial, Irene M, Crown, John, O’Driscoll, Lorraine
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2014
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4234346/
https://ncbi.nlm.nih.gov/pubmed/24655723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-13-71
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados